Drupal.behaviors.print = function(context) {window.print();window.close();}>
Clarient to Offer Qiagen's Therascreen KRAS Assay as CDx for Erbitux
January 30, 2013
Clarient to Offer Qiagen's Therascreen KRAS Assay as CDx for Erbitux
By
a GenomeWeb staff reporter
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
Dx Focus: Clarient to Offer Qiagen Therascreen KRAS Test as Erbitux CDx
January 31, 2013 / PCR Insider
Qiagen Submits EGFR Companion Dx to FDA
January 15, 2013 / GenomeWeb Daily News
NCI Awards Contracts to Insight Genetics to Develop NSCLC CDx
November 12, 2012 / GenomeWeb Daily News
FDA Clears Qiagen KRAS Test as CDx for Erbitux
July 9, 2012 / GenomeWeb Daily News
Clarient Licenses Biomarker IP from Insight Genetics
May 31, 2012 / GenomeWeb Daily News